The FDA-approved drug sofosbuvir inhibits Zika virus infection

Kristen M. Bullard-Feibelman, Jennifer Govero, Zhe Zhu, Vanessa Salazar, Milena Veselinovic, Michael S. Diamond, Brian J. Geiss

Research output: Contribution to journalArticle

116 Scopus citations

Abstract

The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with severe cases causing Guillain-Barré syndrome, congenital malformations, and microcephaly. Currently, there is no available vaccine or therapy to prevent or treat ZIKV infection. We evaluated whether sofosbuvir, an FDA-approved nucleotide polymerase inhibitor for the distantly related hepatitis C virus, could have antiviral activity against ZIKV infection. Cell culture studies established that sofosbuvir efficiently inhibits replication and infection of several ZIKV strains in multiple human tumor cell lines and isolated human fetal-derived neuronal stem cells. Moreover, oral treatment with sofosbuvir protected against ZIKV-induced death in mice. These results suggest that sofosbuvir may be a candidate for further evaluation as a therapy against ZIKV infection in humans.

Original languageEnglish
Pages (from-to)134-140
Number of pages7
JournalAntiviral Research
Volume137
DOIs
StatePublished - Jan 1 2017

Fingerprint Dive into the research topics of 'The FDA-approved drug sofosbuvir inhibits Zika virus infection'. Together they form a unique fingerprint.

  • Cite this

    Bullard-Feibelman, K. M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M. S., & Geiss, B. J. (2017). The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Research, 137, 134-140. https://doi.org/10.1016/j.antiviral.2016.11.023